SPA

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MRK, Research, CRL, New Drug Application, Investment, Eisai, Growth, Sale, Parent, Novin, Focal segmental glomerulosclerosis, Streptococcus, LGND, FSGS, Breakthrough therapy, BLA, AED, GAAP, Therapy, NASH, Liver, NDA, Depreciation, Breast cancer, Total, Forecasting, Perampanel, Shanda, Telecanthus, ID, Retirement, PDUFA, Vaccine, Symantec Endpoint Protection, Type 2 diabetes, Safety, VRNA, Molluscum contagiosum, F2, Acquisition, Caregiver, Merck, AASLD, FDA, Telephone, Food, Pneumonia, Income tax, Hepatology, COVID-19, Element, Patient, SPA, Pharmaceutical industry

Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.

Key Points: 
  • Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.
  • Costs of Captisol sales were $1.6 million for the fourth quarter of 2023, compared with $21.6 million for the same period in 2022, with the decrease due to lower total Captisol sales during the fourth quarter of 2023 and $9.8 million in accelerated depreciation on Captisol manufacturing equipment during the fourth quarter of 2022.
  • Amortization of intangibles was $8.3 million for the fourth quarter of 2023, compared with $8.5 million for the same period in 2022.
  • Travere also announced fourth quarter 2023 results reporting that it received 459 new patient start forms for FILSPARI in the fourth quarter of 2023 and net product sales of $14.9 million for the fourth quarter.

Novo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory Note

Retrieved on: 
Tuesday, February 20, 2024
Telemedicine, Virtual Medicine, Biotechnology, Other Health, Alternative Medicine, Managed Care, Health, General Health, Other Science, Science, Novo, Section 3, Risk, Lung compliance, SPA

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announces today the Company has received a Limited Waiver, specific to Section 3, of the previously disclosed Securities Purchase Agreement, dated April 26, 2023 (“SPA”), between Novo and RC Consulting Group LLC.

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announces today the Company has received a Limited Waiver, specific to Section 3, of the previously disclosed Securities Purchase Agreement, dated April 26, 2023 (“SPA”), between Novo and RC Consulting Group LLC.
  • The waiver exempts any determination of non-compliance associated to Nasdaq’s Minimum Bid Price Requirement rule.
  • This waiver is solely related to any notice of deficiency in accordance with the rule but does not extend to any delisting associated with the aforementioned rule.
  • Except as expressly set forth in the Limited Waiver, the terms, provisions and conditions of the SPA and any other documents related to the SPA shall remain in full force and effect.

Vonage and Telkomsel Collaborate to Drive Ecosystem Digital Innovation by Making Network APIs Available to Developers and Enterprises in Indonesia

Retrieved on: 
Tuesday, March 5, 2024
ASPS, EVP, API, Strategic partnership, Growth, MWC, GNP, Mobile World Congress, Layer 8, CSP, Ecosystem, SPA, Acceleration, Telecommunications, Development

Vonage will collaborate with Telkomsel to expand the power of network APIs for developers, enterprises, and Communications Service Providers (CSPs).

Key Points: 
  • Vonage will collaborate with Telkomsel to expand the power of network APIs for developers, enterprises, and Communications Service Providers (CSPs).
  • By combining Vonage's global communications and network APIs with Telkomsel's leading network APIs, we will be able to deliver new capabilities to enterprises and end users in Indonesia, while accelerating innovation for the network.
  • In facilitating access to network APIs for developers and enterprises, Telkomsel has launched Digihub, a platform that provides access to Telkomsel's network APIs.
  • Vonage's communications and network APIs make it easy for developers to embed communications capabilities into applications, systems, and workflows.

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS

Retrieved on: 
Friday, February 23, 2024
Brainstorm, Therapy, ALS, Marketing, FDA, Food, Element, SPA, Pharmaceutical industry

The submission follows an in-person meeting that BrainStorm held with the FDA in December 2023.

Key Points: 
  • The submission follows an in-person meeting that BrainStorm held with the FDA in December 2023.
  • The interactions leading up to this submission have provided guidance on advancing the planned Phase 3b trial.
  • Participating in an SPA program would allow BrainStorm to reach consensus with the FDA on its clinical trial design, including the proposed statistical analysis, before the study is initiated.
  • Stacy Lindborg, Ph.D., Co-CEO of BrainStorm added, "BrainStorm remains deeply committed to the ALS community.

Å Entelios and Solar Power Accelerator enter into a strategic collaboration for the expansion of Energy as a Service including solar plants and energy storage systems

Retrieved on: 
Tuesday, February 20, 2024
Carbon, Energi, EV, Cloud computing, Solar, IPP, Carbon footprint, PPA, Entrepreneurship, C&I, Energy, SPA, Electricity, Solar energy, Renewable energy

These services encompass planning, procurement, financing, operation, service, and maintenance for solar plants and battery storage solutions.

Key Points: 
  • These services encompass planning, procurement, financing, operation, service, and maintenance for solar plants and battery storage solutions.
  • Å Entelios is part of Norway's leading power group, Å Energi, which is owned by Norwegian Statkraft and 30 municipalities.
  • Solar Power Accelerator AB (SPA) is an independent power producer (IPP), developer, and EaaS provider of large-scale rooftop-based solar power.
  • "The collaboration with Å Entelios allows us to focus on cost-effective and less complex energy projects with increased customer satisfaction.

Cryo-EM: Visualizing Biomolecules with High-Throughput Single Particle Analysis, Webinar Hosted by Xtalks March 6, 2024

Retrieved on: 
Thursday, February 15, 2024
Protein, Nobel Prize in Chemistry, Data collection, Wild Arms, JEOL, Classification, Cryogenic electron microscopy, Nobel Prize, SPA

TORONTO, Feb. 15, 2024 /PRNewswire-PRWeb/ -- The field of cryogenic electron microscopy (cryo-EM) exploded in popularity during the "resolution revolution" in the 2010s, leading to the 2017 Nobel Prize in Chemistry awarded to Jacques Dubochet, Joachim Frank and Richard Henderson "for developing cryo-electron microscopy for the high-resolution structure determination of biomolecules in solution." Cryo-EM techniques such as single particle analysis (SPA) now allow structure determination of biomolecules at resolutions previously only reached by X-ray crystallography. Cryo-EM offers many new possibilities as it does not require protein crystallization and allows structural determination of large protein complexes imaged in frozen solution or even in the cellular environment.

Key Points: 
  • The featured speaker will discuss the features of the JEOL CRYO ARM 200kV and 300kV cryo-TEMs.
  • Cryo-EM techniques such as single particle analysis (SPA) now allow structure determination of biomolecules at resolutions previously only reached by X-ray crystallography.
  • Register for this webinar to learn about innovative approaches in cryo-EM, including high-throughput single particle analysis and more.
  • Join Emmanuel Smith, Senior Application Specialist for Cryo-EM, JEOL USA, for the live webinar on Wednesday, March 6, 2024, at 2pm EST (11am PST).

TIAN RUIXIANG Holdings Ltd’s Subsidiary Enters into Sale and Purchase Agreement for Licensed Insurance Broker in Hong Kong

Retrieved on: 
Wednesday, February 14, 2024
Acquisition, Sale, SPA, TRX, Insurance, Property management

The Target is a licensed insurance brokerage in Hong Kong.

Key Points: 
  • The Target is a licensed insurance brokerage in Hong Kong.
  • This strategic acquisition represents a milestone in the Company's business to expand into the Hong Kong insurance brokerage market.
  • Mr. Zhe Wang, Chairman and CEO of TIAN RUIXIANG Holdings Ltd, stated, "This acquisition aligns with our long-term strategic vision of establishing a presence beyond mainland China’s insurance brokerage market.
  • We are excited about the growth opportunities in the Hong Kong market and are committed to leveraging our expertise and resources in order to capitalize on such opportunities."

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

Retrieved on: 
Wednesday, February 14, 2024
AmerisourceBergen, EMA, Injection, Committee, Fiscal, CRL, Outlook, MAA, Ranibizumab, FDA, Calendar, Completion, Bevacizumab, Symantec Endpoint Protection, Chemistry, Therapy, CHMP, European Medicines Agency, AMD, Patient, SPA, Retina, CMC

ISELIN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced financial results for first quarter fiscal year 2024 and provided a corporate update.

Key Points: 
  • ISELIN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced financial results for first quarter fiscal year 2024 and provided a corporate update.
  • Importantly, the first subject was enrolled in NORSE EIGHT in January 2024,” commented Russell Trenary, President and Chief Executive Officer.
  • In January 2024, Outlook Therapeutics announced that it received written agreement on the NORSE EIGHT trial protocol from the FDA under a SPA for NORSE EIGHT.
  • Outlook Therapeutics expects NORSE EIGHT topline results and resubmission of the ONS-5010 BLA by the end of calendar year 2024.

CHESAPEAKE ENERGY CORPORATION, DELFIN LNG AND GUNVOR SIGN LONG-TERM LNG LIQUEFACTION OFFTAKE AGREEMENT INDEXED TO JAPAN KOREA MARKER

Retrieved on: 
Tuesday, February 13, 2024
FOB, JKM, Natural gas, Carbon, Executive Committee, HOA, SPA, Henry Hub, Chesapeake Energy

OKLAHOMA CITY, Feb. 13, 2024 /PRNewswire/ -- Chesapeake Energy Corporation (NASDAQ: CHK, together with certain of its subsidiaries, collectively, "Chesapeake"), Delfin LNG LLC ("Delfin") and Gunvor Group Ltd, through Gunvor Singapore Pte Ltd ("Gunvor"), today announced the entrance into a liquefied natural gas (LNG) export deal that includes executed Sales and Purchase Agreements ("SPA") for long-term liquefaction offtake.

Key Points: 
  • OKLAHOMA CITY, Feb. 13, 2024 /PRNewswire/ -- Chesapeake Energy Corporation (NASDAQ: CHK, together with certain of its subsidiaries, collectively, "Chesapeake"), Delfin LNG LLC ("Delfin") and Gunvor Group Ltd, through Gunvor Singapore Pte Ltd ("Gunvor"), today announced the entrance into a liquefied natural gas (LNG) export deal that includes executed Sales and Purchase Agreements ("SPA") for long-term liquefaction offtake.
  • These volumes will represent 0.5 mtpa of the previously announced up to 2 mtpa HOA with Gunvor.
  • We are pleased to formalize our agreement which provides diversification and access to global LNG pricing while enabling the delivery of affordable, reliable, lower carbon energy to markets in need."
  • Dudley Poston, Delfin CEO, said: "We are excited to partner with a premier company like Chesapeake.

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Retrieved on: 
Tuesday, February 13, 2024
Injection, FDA, Consultant, Eye, Diabetic retinopathy, Macular degeneration, AMD, Patient, SPA, Clinical trial, Axitinib, SOL, Research, Pharmaceutical industry

The Company previously announced FDA agreement on its Special Protocol Assessment (SPA) Agreement Modification on January 25th.

Key Points: 
  • The Company previously announced FDA agreement on its Special Protocol Assessment (SPA) Agreement Modification on January 25th.
  • “The screening of these subjects in the pivotal Phase 3 SOL-1 trial of AXPAXLI marks an exciting milestone for Ocular Therapeutix,” said Antony Mattessich, CEO of Ocular Therapeutix.
  • We believe that AXPAXLI could set a new standard in wet AMD therapy by significantly extending time between treatments.
  • “Clinical trials like the SOL-1 study for AXPAXLI represent a critical step forward in our pursuit of more patient-centric treatments for wet AMD.